Company research
Keenova Therapeutics plc
CIK 1567892Updated Sep 26, 2026
Name history
Mallinckrodt plc · through Nov 10, 2025
Filing activity
Latest filing
50 filings on record · 10-Q, 8-K, 4, SD, ARS, DEF 14A.
About the company
Keenova Therapeutics is a leading U.S.-focused branded therapeutics company that strives to help patients with rare or unaddressed conditions live happier and healthier lives. Keenova’s rare disease capabilities underpin our diversified brands portfolio, which is focused across a wide range of specialty therapeutic areas of significant unmet need. These include rheumatology, ophthalmology, nephrology, neurology, pulmonology, orthopedics, urology, and neonatal respiratory critical care.
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Other Events
Items 8.01
4 filing
4 filing
Show 5 more recent filings
4 filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Other Events
Items 8.01, 9.01
4 filing
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 5,628,600,000Source | 3,302,600,000Source | 3,733,600,000Source | 6,013,800,000Source |
| Property, Plant and Equipment, NetUSD | 185,400,000Source | 390,600,000Source | 321,700,000Source | 457,600,000Source |
| GoodwillUSD | 31,800,000Source | — | — | — |
| Intangible Assets, Net (Excluding Goodwill)USD | 2,229,600,000Source | 419,400,000Source | 608,400,000Source | 2,843,800,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 812,800,000Source | 382,600,000Source | 262,700,000Source | 409,500,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 299,100,000Source | 395,300,000Source | 377,500,000Source | 405,300,000Source |
| Inventory, NetUSD | 553,500,000Source | 664,900,000Source | 982,700,000Source | 947,600,000Source |
| Assets, CurrentUSD | 1,920,300,000Source | 1,629,100,000Source | 1,761,800,000Source | 2,035,800,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 254,900,000Source | — | — | — |
| Operating Lease, Right-of-Use AssetUSD | 59,200,000Source | 56,300,000Source | 50,900,000Source | 38,100,000Source |
| Other Assets, NoncurrentUSD | 606,700,000Source | 211,700,000Source | 240,700,000Source | 201,100,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 3,563,400,000Source | 1,656,800,000Source | 2,573,400,000Source | 4,400,100,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | — | — | — |
| Additional Paid in CapitalUSD | 2,115,500,000Source | 1,199,800,000Source | 1,194,600,000Source | 2,191,000,000Source |
| Retained Earnings (Accumulated Deficit)USD | -51,700,000Source | 439,700,000Source | -38,200,000Source | -588,200,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 1,000,000Source | 6,100,000Source | 3,600,000Source | 10,800,000Source |
| Stockholders' Equity Attributable to ParentUSD | 2,065,200,000Source | 1,645,800,000Source | 1,160,200,000Source | 1,613,700,000Source |
| Liabilities and EquityUSD | 5,628,600,000Source | 3,302,600,000Source | 3,733,600,000Source | 6,013,800,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 672,100,000Source | 431,400,000Source | 501,200,000Source | 743,800,000Source |
| Operating Lease, Liability, CurrentUSD | 11,900,000Source | 10,800,000Source | 10,500,000Source | 10,300,000Source |
| Accounts Payable, CurrentUSD | 77,900,000Source | 57,800,000Source | 100,400,000Source | 114,000,000Source |
| Operating Lease, Liability, NoncurrentUSD | 48,700,000Source | 45,000,000Source | 44,800,000Source | 30,400,000Source |
| Deferred Income Tax Liabilities, NetUSD | 115,600,000Source | 100,000Source | 0Source | 300,000Source |
| Other Liabilities, NoncurrentUSD | 112,500,000Source | 102,900,000Source | 92,500,000Source | 78,400,000Source |
| Additional Financial Items | ||||
| Long-term Debt, Current MaturitiesUSD | 15,000,000Source | 3,900,000Source | 6,500,000Source | 44,100,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | 1,641,300,000Source | 3,490,000,000Source |
| Restricted Cash and Investments, CurrentUSD | — | 21,500,000Source | 40,800,000Source | 20,600,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 130,500,000Source | 117,200,000Source | 490,300,000Source | 675,800,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 43,700,000Source | 7,200,000Source | 8,900,000Source | 10,200,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 16,300,000Source | 30,200,000Source | 65,500,000Source | -98,200,000Source |
| Increase (Decrease) in InventoriesUSD | -187,400,000Source | -261,500,000Source | -108,200,000Source | 14,000,000Source |
| Increase (Decrease) in Accounts PayableUSD | 0Source | -26,300,000Source | -37,200,000Source | -1,100,000Source |
| Deferred Income Tax Expense (Benefit)USD | -54,200,000Source | 158,700,000Source | -319,100,000Source | -59,900,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | 160,700,000Source | -412,100,000Source | 455,400,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | 790,500,000Source | -52,700,000Source | -37,800,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | -2,400,000Source | -4,900,000Source | -1,200,000Source | -1,800,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 50,400,000Source | 113,200,000Source | 53,900,000Source | 55,300,000Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | — | — | — | 0Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | -846,400,000Source | 273,200,000Source | -137,500,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | -6,300,000Source | -600,000Source | -100,000Source | 0Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 508,300,000Source | 102,300,000Source | -193,300,000Source | 278,200,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 954,000,000Source | 445,700,000Source | 273,400,000Source | 1,405,200,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 170,000,000Source | 232,000,000Source | 316,800,000Source | 243,200,000Source |
| Income Taxes Paid, NetUSD | 6,200,000Source | 25,700,000Source | -128,000,000Source | -160,000,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | -2,500,000Source | -1,700,000Source | — |
| Additional Financial Items | ||||
| Accretion ExpenseUSD | — | — | 176,700,000Source | — |
| Share-based Payment Arrangement, ExpenseUSD | 46,400,000Source | 7,200,000Source | 8,900,000Source | 10,200,000Source |
| Amortization of Intangible AssetsUSD | 115,400,000Source | 80,300,000Source | 449,600,000Source | 581,100,000Source |
| DepreciationUSD | 15,100,000Source | 36,500,000Source | 40,700,000Source | 94,700,000Source |
| Disposal Group, Not Discontinued Operation, Gain (Loss) on DisposalUSD | -5,900,000Source | 754,400,000Source | — | -800,000Source |
| Gain (Loss) on Disposition of BusinessUSD | — | 754,400,000Source | 0Source | -800,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | 15,900,000Source | -19,700,000Source | — | 0Source |
| GoodwillUSD | 31,800,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -457,500,000Source | 476,600,000Source | -1,631,300,000Source | -723,500,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | -32,000,000Source | 1,300,000Source | 0Source | 6,100,000Source |
| Income Tax Expense (Benefit)USD | -23,800,000Source | 137,900,000Source | -277,800,000Source | -106,300,000Source |
| InterestExpenseNonoperatingUSD | 168,800,000Source | — | — | — |
| Inventory Write-downUSD | 31,300,000Source | — | 44,000,000Source | 11,500,000Source |
| Net Income (Loss) Attributable to ParentUSD | -489,500,000Source | 477,900,000Source | -1,631,300,000Source | -717,400,000Source |
| Other Nonoperating Income (Expense)USD | 6,100,000Source | -9,100,000Source | -6,500,000Source | 22,000,000Source |
| Payments of Financing CostsUSD | 0Source | 0Source | 4,100,000Source | 0Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | 0Source |
| Restricted Cash and Investments, CurrentUSD | — | 21,500,000Source | 47,000,000Source | 24,000,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 1,430,600,000Source | 1,979,700,000Source | 1,622,900,000Source | 2,208,800,000Source |
| Unrealized Gain (Loss) on DerivativesUSD | -5,200,000Source | — | — | — |
| Unrealized Gain (Loss) on InvestmentsUSD | 1,700,000Source | 17,400,000Source | 10,100,000Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2021 |
|---|---|---|---|---|
| Cost of RevenueUSD | 787,800,000Source | 1,152,600,000Source | 1,300,500,000Source | 1,317,100,000Source |
| Selling, General and Administrative ExpenseUSD | 761,300,000Source | 566,800,000Source | 448,200,000Source | 581,800,000Source |
| Operating Income (Loss)USD | -348,200,000Source | 90,200,000Source | -517,400,000Source | -202,900,000Source |
| Other Nonoperating Income (Expense)USD | 6,100,000Source | -9,100,000Source | -6,500,000Source | 22,000,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -481,300,000Source | 614,500,000Source | -1,909,100,000Source | -829,800,000Source |
| Income Tax Expense (Benefit)USD | -23,800,000Source | 137,900,000Source | -277,800,000Source | -106,300,000Source |
| Net Income (Loss) Attributable to ParentUSD | -489,500,000Source | 477,900,000Source | -1,631,300,000Source | -717,400,000Source |
| Earnings Per Share, BasicUSD per share | -17.5Source | 24.26Source | -122.75Source | -8.47Source |
| Earnings Per Share, DilutedUSD per share | -17.5Source | 24.17Source | -122.75Source | -8.47Source |
| Total Revenue | — | — | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 28,000,000Source | 19,700,000Source | 13,300,000Source | 84,700,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 28,000,000Source | 19,800,000Source | 13,300,000Source | 84,700,000Source |
| Interest Expense (non-operating)USD | 168,800,000Source | — | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 115,400,000Source | 80,300,000Source | 449,600,000Source | 581,100,000Source |
| Current Income Tax Expense (Benefit)USD | 30,400,000Source | -20,800,000Source | 41,300,000Source | -46,400,000Source |
| Gross ProfitUSD | 642,800,000Source | 827,100,000Source | 322,400,000Source | 891,700,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -457,500,000Source | 476,600,000Source | -1,631,300,000Source | -723,500,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -363,400,000Source | 675,100,000Source | -3,628,800,000Source | -512,200,000Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | -16.35Source | 24.2Source | -122.75Source | -8.54Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | -16.35Source | 24.11Source | -122.75Source | -8.54Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | -32,000,000Source | 1,300,000Source | 0Source | 6,100,000Source |
| Interest ExpenseUSD | — | 228,300,000Source | 507,200,000Source | 222,600,000Source |
| Interest Income, OtherUSD | 19,600,000Source | 27,000,000Source | 14,700,000Source | 1,900,000Source |
| Research and Development ExpenseUSD | 90,700,000Source | 115,700,000Source | 97,100,000Source | 205,200,000Source |
| Restructuring and Related Cost, Incurred CostUSD | -2,200,000Source | — | — | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 1,430,600,000Source | 1,979,700,000Source | 1,622,900,000Source | 2,208,800,000Source |
Offerings
Registration 333-286694
Filing attachments
tm2619951d1_ex99-1.htm · 8-K · 2026-07-08
EX-99.1 2 tm2619951d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Keenova Announces Positive Phase 3 Results in Clinical Trial of XIAFLEX® (collagenase clostridium histolyticum) for Treating Plantar Fibromatosis DUBLIN, July 8, 2026 - Keenova Therapeutics plc announced today positive results from its Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum) for the treatment of plantar fibromatosis, a chronic medical condition that causes nodules composed primarily of excess colla…
Read attachment ↗tm2530694d1_ex99-1.htm · 8-K · 2025-11-10
EX-99.1 9 tm2530694d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Mallinckrodt Completes Spin-Off of Par Health, Introduces Keenova Therapeutics Keenova Focused on Advancing Therapies to Address Unmet Patient Needs Company Intends to Pursue Public Equity Listing in 2026 DUBLIN, Nov. 10, 2025 -- Mallinckrodt plc ("Mallinckrodt") today announced the completion of the planned spin-off of its Par Health generic pharmaceuticals and sterile injectables businesses. Moving ahead, Mallinckrodt will be k…
Read attachment ↗tm2530694d1_ex99-2.htm · 8-K · 2025-11-10
EX-99.2 10 tm2530694d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Disclaimer Ernst & Young LLP (EY) prepared the attached Report only for Mallinckrodt Plc (the "Client") pursuant to an agreement solely between EY and Client. EY did not perform its services on behalf of or to serve the needs of any other person or entity. Accordingly, EY expressly disclaims any duties or obligations to any other person or entity based on its use of the attached Report. Any other person or entity must perform its …
Read attachment ↗tm2529501d1_ex99-1.htm · 8-K · 2025-10-30
EX-99.1 2 tm2529501d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Information Statement dated October 30, 2025 PROMPT ACTION IS REQUIRED BY ALL BROKERS AND SHAREHOLDERS PLEASE COMPLETE YOUR CERTIFICATION FORM AS SOON AS POSSIBLE - IF MALLINCKRODT HAS NOT RECEIVED SUFFICIENT VALID CERTIFICATION FORMS FROM QUALIFIED SHAREHOLDERS BY NOVEMBER 7, 2025, AT 5:30 P.M. (EASTERN TIME IN THE UNITED STATES) (OR SUCH OTHER DATE AS MAY BE DETERMINED BY THE MALLINCKRODT BOARD IN ITS SOLE AND ABSOLUTE DISCRETIO…
Read attachment ↗tm2529501d1_ex99-2.htm · 8-K · 2025-10-30
EX-99.2 3 tm2529501d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 INDEX TO FINANCIAL STATEMENTS Page Mallinckrodt Specialty Generics Business Condensed Combined Financial Statements (Unaudited) F-1 Condensed Combined Statements of Operations (Unaudited) F-2 Condensed Combined Statements of Comprehensive Operations (Unaudited…
Read attachment ↗tm2529406d1_ex99-1.htm · 8-K · 2025-10-24
EX-99.1 2 tm2529406d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 PROMPT ACTION IS REQUIRED BY ALL BROKERS AND SHAREHOLDERS PLEASE RETURN THIS CERTIFICATION FORM IMMEDIATELY FAILURE TO PROPERLY AND TIMELY COMPLETE THIS CERTIFICATION FORM IN ACCORDANCE WITH THE INSTRUCTIONS IN THE INFORMATION STATEMENT WILL RESULT IN YOUR RIGHT TO RECEIVE PAR HEALTH COMMON STOCK OR CASH IN THE SPIN-OFF LAPSING AND EXPIRING Spin-off of Par Health On October 10, 2025, Mallinckrodt plc (“Mallinckrodt”)…
Read attachment ↗